The therapeutic use of antibodies is restricted by limited access of antibodies to intracellular compartments. In order to overcome this limitation, we developed a cell-penetrating monoclonal antibody, mAb 3E10, as an intracellular delivery vehicle for the intracellular and intranuclear delivery of antibodies constructed as bispecific single-chain Fv fragments. Since MDM2 is an important target in cancer therapy, we selected monoclonal antibody 3G5 for intracellular transport. mAb 3G5 binds MDM2 and blocks binding of MDM2 to p53. Here we show that the resulting 3E10-3G5 bispecific antibody retains cell-penetrating and MDM2-binding activity, increases tumor p53 levels, and inhibits growth of MDM2-addicted tumors. The use of cell-penetrating bispecific antibodies in targeted molecular therapy will significantly broaden the spectrum of accessible intracellular targets and may have a profound impact in cancer therapy.
Introduction
Cell membranes are impermeable to most macromolecules, and current approaches to the therapeutic regulation of intracellular targets are therefore largely based on the use of small molecules that are capable of passive diffusion into cells. However, small molecule inhibitors are prone to causing off-target effects that can result in significant toxicity (1) . By contrast, antibodies have excellent binding specificity and minimal off-target effects, but most antibodies do or located on the cell membrane. Gene therapy can be used to produce intracellular antibodies, but its use is not justified because of potential toxicity.
We previously identified a rare monoclonal anti-DNA antibody, 3E10, which penetrates living cells and localizes in the nucleus through an equilibrative nucleoside transporter without causing any apparent harm to the cell (2, 3) . 3E10
and its single chain variable fragment (3E10 scFv) have been developed as an intracellular delivery system for macromolecules (4) (5) (6) (7) (8) (9) . Notably, after localizing in the cell nucleus, 3E10 scFv is largely degraded within 4 hours, thus further minimizing any potential toxicity (unpublished data). 3E10 scFv has previously mediated intracellular delivery of biologically active cargo proteins such as p53 and Hsp70 in vivo (7, 9) , and we hypothesized that 3E10 scFv might also be capable of delivering biologically active antibody fragments into cells.
MDM2, an E3 ubiquitin ligase that down-regulates the function of p53, is associated with numerous malignancies and is an important target in cancer therapy. Inhibition of MDM2 increases active p53 levels and is associated with induction of senescence in human melanoma cell lines (10) . The monoclonal antibody 3G5 was previously shown to bind critical residues at the N-terminus of MDM2 that are required for binding to p53, and 3G5 is, therefore, an excellent candidate for application as a targeted inhibitor of MDM2 (11) (12) (13) (14) (15) . However, 3G5 is unable to penetrate into cells. We therefore tested the ability of 3E10 scFv to deliver a functional single chain variable fragment of the 3G5 antibody into tumor cells. 3G5 Vk and VH were cloned by RT-PCR from hybridoma RNA with degenerate primers designed to identify mouse immunoglobulin variable region genes, and 3G5 scFv was constructed as described previously (4) . Variable region heavy and light chains were attached with a (GGGGS) 3 linker. The Fv fragments were connected with a linker composed of CH1 sequences combined with a swivel sequence (6). 3E10-3G5 bispecific scFv cDNA was constructed in pPicZαA between the EcoRI and XbaI cloning sites in frame with the C-terminal myc-his 6 tag. Plasmids were transfected into X-33 cells, and a high-secreting clone was identified as described previously (6) . Bispecific antibody was purified from X-33 
Cell penetration assay
COS-7 cells were incubated with control media, media containing 10 μM 3E10 scFv, or media containing 10 μM 3E10-3G5 for one hour. Media was then removed from the cells, and cells were washed, fixed, and stained with an antimyc antibody as described previously (3).
In vitro assays of 3E10-3G5 cytotoxicity
Cells were grown in DMEM with 10% FCS. Adherent cells were removed with EDTA and distributed in 96-well plates overnight in the presence of medium alone, 3E10, or 3E10-3G5. Growth was evaluated after 3 days by counting cells.
Results were expressed as percent total cell number (relative to control) ± S.D.
In vivo assays of 3E10-3G5 cytotoxicity
Animal studies were done under a protocol approved by the Veterans 
Western blot assays
UACC-257 tumors were excised, and tumor tissue was lysed in 2% SDS.
Protein (20 μg) from each tumor was electrophoresed in a 4-20% polyacrylamide gradient gel and then transblotted to a nylon membrane. Western blots were probed with antibodies to p53, MDM2, and actin.
Statistical Analyses
Significant differences in tumor growth were determined by Students t test.
Results

3E10-3G5 retains the MDM2-binding activity of 3G5 and the cell-penetrating activity of 3E10
A 3E10-3G5 bispecific antibody composed of the single chain variable fragments of the cell-penetrating 3E10 antibody and the anti-MDM2 3G5 antibody was produced as a secreted protein by Pichia pastoris X-33 cells transfected with pPicZαA containing the bispecific scFv cDNA (Fig. 1A) . 3E10-3G5 was purified from yeast supernatant by metal chelation chromatography on Ni-NTA-Agarose as described previously (6) (Fig. 1B) . Purified 3E10-3G5 was used as a probe for MDM2 in a Western blot assay on lysates from MC-7 cells 
over-expressing MDM2, and was found to recognize and bind MDM2 similar to the full 3G5 antibody and with similar binding specificity (Fig. 1C) . MC-7 cells were selected as a convenient source of MDM2. Next, 3E10-3G5 was applied to COS-7 cells in culture and was observed to penetrate into the cells and localize in nuclei similar to 3E10 scFv alone (Fig. 1D) . COS-7 cells over-express hENT-2 and served as a convenient model cell to demonstrate cellular penetration by the bispecific scFv. These results demonstrate that the 3E10-3G5 bispecific antibody retains the cell-penetrating activity of 3E10 scFv and the MDM2-binding activity of 3G5 scFv.
3E10-3G5 impairs the growth of MDM2-addicted melanoma cells
We next investigated the impact of 3E10-3G5 on melanoma cells known to be sensitive to MDM2 inhibition (10) . UACC-257 melanoma cells were incubated for 3 days with media containing concentrations of 3E10-3G5 ranging from 0-10 μM. 3E10 and 3G5 alone were used as controls and had no observable effect on the growth or morphology of UACC-257 melanoma cells compared to culture medium (Fig. 2C) . However, 3E10-3G5 delayed the growth of the cells in a dose-responsive manner, with significant growth delay observed at a dose of 10 μM (Fig. 2A) . A similar effect was observed in additional MDM2-addicted melanoma cell lines, with marked inhibition of growth and distinct morphological changes observed in all of the melanoma cell lines tested (Fig. 2B and 2C). As expected, 3E10 and 3G5 alone had no apparent effect on any of the melanoma cell lines (Fig. 2C) . Importantly, 3E10-3G5 had only a mild impact on the growth of murine 3T3 transformed fibroblasts and had no effect on the growth of BJ primary human fibroblasts (Fig. 2B) . Taken together these data suggest that 3E10-3G5 successfully inhibited MDM2 in vitro and caused a growth delay specifically in the MDM2-addicted cells.
3E10-3G5 inhibits growth of melanoma tumors in vivo
The activity of 3E10-3G5 in vivo was tested in a human melanoma xenograft model. Nude mice were injected subcutaneously with 1X10 Mice that developed tumors were then followed closely and tumor volumes were measured. Importantly, treatment with 3E10-3G5 was not associated with any clinical toxicity, as treated mice were indistinguishable from control mice with respect to their appearance and activity. However, treatment with 3E10-3G5 significantly inhibited tumor growth at day 20 (p=0.041) and at the termination of the experiment on day 22 (p=0.026) (Fig. 3A-C) . In order to probe the mechanism responsible for tumor growth inhibition, we evaluated the relative levels of p53 and MDM2 in representative tumors from three untreated mice and three mice treated with 3E10-3G5. Treatment with 3E10-3G5 increased the expression of MDM2 and p53 as shown in Western blots of tumor lysates probed with antibodies to p53 and MDM2 (Fig. 3D) . Actin served as a loading control.
These results are similar to changes in MDM2 and p53 levels observed in cells 
Discussion
We have demonstrated that treatment with a 3E10-3G5 bispecific antibody impairs the growth of melanoma cells in vitro and in vivo. This growth delay is likely the result of increased levels of activated p53 that have been freed from inhibition by MDM2 by the action of the 3G5 antibody fragment. In keeping with this hypothesis, elevated levels of p53 were observed in tumors in mice treated with the bispecific antibody. We also noted that these tumors exhibited increased levels of MDM2, which is consistent with results obtained by others with MDM2 inhibitors such as Nutlin-3, and is likely the result of increased levels of p53 driving additional production of MDM2 (10) . Since MDM2 has numerous p53-independent effects (10) it is possible that the impact of 3E10-3G5 on the melanoma cells and tumors is the result of an effect on diverse metabolic pathways in addition to its impact on p53 function. Although we administered micromolar amounts of 3E10-3G5 to mice, only nanomolar amounts are internalized intracellularly consistent with antigen-binding specific effects.
We previously constructed and demonstrated efficacy of a cell-penetrating bispecific antibody composed of 3E10 scFv and the scFv fragment of mAb PAb421, an antibody that binds and restores the function of some p53 mutants (6) . In the present study we have extended our cell-penetrating bispecific antibody technology by demonstrating the effectiveness of this approach in 
